Cartesian Therapeutics (NASDAQ:RNAC) and AngioSoma (OTCMKTS:SOAN) Head-To-Head Comparison

Cartesian Therapeutics (NASDAQ:RNAC) and AngioSoma (OTCMKTS:SOAN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Cartesian Therapeutics and AngioSoma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
AngioSoma	N/A	N/A	-1,245.34%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cartesian Therapeutics and AngioSoma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	6	0	2.75
AngioSoma	0	0	0	0	0.00

Cartesian Therapeutics currently has a consensus price target of $42.50, suggesting a potential upside of 314.23%. Given Cartesian Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Cartesian Therapeutics is more favorable than AngioSoma.

Valuation and Earnings

This table compares Cartesian Therapeutics and AngioSoma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$34.17 million	7.79	-$219.71 million	($52.83)	-0.19
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A

AngioSoma has lower revenue, but higher earnings than Cartesian Therapeutics.

Volatility and Risk

Cartesian Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500.

Institutional & Insider Ownership

86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 0.0% of AngioSoma shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cartesian Therapeutics beats AngioSoma on 8 of the 10 factors compared between the two stocks.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.